TacticScaleWhat Zoetis Does & How It Makes Money (ZTS)
Updated October 2026 · reflects Zoetis's latest reported financials
Animal health company making medicines, vaccines and diagnostics for pets and livestock. Zoetis makes money by selling animal medicines, vaccines, diagnostic instruments, test kits and reagents, and related services to veterinarians, livestock producers and pet owners.
How Zoetis makes money
Zoetis makes money by selling animal medicines, vaccines, diagnostic instruments, test kits and reagents, and related services to veterinarians, livestock producers and pet owners. Its companion-animal and livestock products are sold both in the US and internationally.
What Zoetis does
Zoetis Inc. is an animal health company. It discovers, develops, manufactures and sells medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health solutions. Its products cover companion animals (dogs, cats and horses) and livestock (cattle, swine, poultry, fish and sheep). Its main therapeutic areas are parasiticides, vaccines, dermatology, anti-infectives, and pain and sedation. Its diagnostics business includes point-of-care instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors. It also sells nutritionals. It sells to veterinarians, livestock producers and pet owners in the US and internationally, and it works with Blacksmith Medicines to develop new antibiotics for animals. Zoetis was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
Products & services
- Parasiticides for pets and livestock
- Animal vaccines
- Dermatology and pain/sedation medicines
- Anti-infectives
- Point-of-care diagnostic instruments and rapid tests
- Reference lab services, genetic tests and precision animal health
What is Zoetis worth?
On an owner-earnings DCF, Zoetis's most-likely value is about $139 versus a recent price near $75 (86% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$66) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Elanco Animal Health (ELAN) · Phibro Animal Health (PAHC) · Merck (MRK) · Viatris (VTRS) · Zhejiang Medicine (600216.SS)